Abstract
43 patients with stage III NSCLC (non-small cell lung cancer) entered a phase II study aimed at evaluating the toxicity and the activity of a combined modality programme including an accelerated split-course schedule (type B) of thoracic radiation therapy and a combination chemotherapy with vinorelbine and carboplatin. An objective response was achieved in 18/42 evaluable patients (5 complete and 13 partial responses), for an overall response rate of 43% (95% confidence interval, 28-58%). Four complete responses had a duration which exceeded 16 months. Treatment was well tolerated; grade III myelotoxcity occurred in only 14% of patients and treatment was delayed in only 2 cases because of grade 3 oesophagitis. Both tolerability and efficacy data suggest that this regimen holds promise for the treatment of patients with stage III NSCLC.
Original language | English |
---|---|
Pages (from-to) | 1901-1904 |
Number of pages | 4 |
Journal | European Journal of Cancer |
Volume | 32 |
Issue number | 11 |
DOIs | |
Publication status | Published - Oct 1996 |
Keywords
- Accelerated split-course radiotherapy
- Carboplatin
- Non-small cell lung cancer
- Vinorelbine
ASJC Scopus subject areas
- Cancer Research
- Hematology
- Oncology